Journal article Open Access

Single Dose, Two-way Crossover Bioequivalence Study of Favipiravir Tablet in Healthy Male Subjects

Onursal Sağlam; Gökçe Demiray*; Berrak Güney; Emel Doğan-Kurtoğlu; Merve G. Ulusoy; Nihal Saraner; Gamze Sevici; Muradiye Nacak; Aydın Erenmemişoğlu; Vildan Tüzer


Background: As WHO expresses, coronavirus disease 2019 (COVID-19) is the infectious disease caused by the most recently discovered

coronavirus. This new virus and disease were unknown before the outbreak began in Wuhan, China, in December 2019. COVID-

19 is now a pandemic affecting many countries globally. Antiviral agents play fundamental role in Covid-19 treatment. Favipiravir is

one of the favored agents and it still draws attention of generic drug industry which is constitutional for drug accessibility.

Objective: The aim of this study is to demonstrate the bioequivalence of a new Favipiravir tablet formulation as compared to the

reference tablet formulation in healthy male subjects under fasting conditions.To prove the bioequivalence, a randomised, single oral

dose, cross-over, two-period study was carried out in 30 healthy subjects under fasting conditions. Plasma Favipiravir levels were

quantified by using an in-house-developed high performance Liquid Chromatography Coupled to Tandem Mass Spectrometry (LCMS/

MS) method.

Results: The 90% CIs for the test/reference geometric mean ratios of the Cmax and AUC0-tlast were 92.92 – 119.89% and 94.00 –

99.77%, respectively.

Conclusions: This single-dose study has shown that the test and reference Favipiravir products met the required bioequivalence

criteria. Besides, both products were well tolerated and safe.

Files (555.9 kB)
Name Size
555.9 kB Download
All versions This version
Views 4242
Downloads 1919
Data volume 10.6 MB10.6 MB
Unique views 3939
Unique downloads 1919


Cite as